Works matching AU Peyrin ‐ Biroulet, L.

Results: 81
    1

    A17 EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY.

    Published in:
    Journal of the Canadian Association of Gastroenterology, 2021, v. 4, p. 21, doi. 10.1093/jcag/gwab002.016
    By:
    • Peyrin-Biroulet, L;
    • Loftus, E V;
    • Danese, S;
    • Vermeire, S;
    • Sandborn, W J;
    • Fogel, R;
    • Nijhawan, S;
    • Kempinski, R;
    • Filip, R;
    • Hospodarskyy, I;
    • McNally, J;
    • Yun, C;
    • Zhao, S;
    • Liu, X;
    • Tasset, C;
    • Besuyen, R;
    • Watanabe, M;
    • Schreiber, S;
    • Rogler, G;
    • Hibi, T
    Publication type:
    Article
    2
    3
    4
    5
    6
    7
    8
    9

    Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 4, p. 485, doi. 10.1111/apt.14419
    By:
    • Tadbiri, S.;
    • Peyrin‐Biroulet, L.;
    • Serrero, M.;
    • Filippi, J.;
    • Pariente, B.;
    • Roblin, X.;
    • Buisson, A.;
    • Stefanescu, C.;
    • Trang‐Poisson, C.;
    • Altwegg, R.;
    • Marteau, P.;
    • Vaysse, T.;
    • Bourrier, A.;
    • Nancey, S.;
    • Laharie, D.;
    • Allez, M.;
    • Savoye, G.;
    • Gilletta, C.;
    • Gagniere, C.;
    • Vuitton, L.
    Publication type:
    Article
    10
    11
    12
    13

    One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2017, v. 46, n. 3, p. 310, doi. 10.1111/apt.14167
    By:
    • Amiot, A.;
    • Serrero, M.;
    • Peyrin‐Biroulet, L.;
    • Filippi, J.;
    • Pariente, B.;
    • Roblin, X.;
    • Buisson, A.;
    • Stefanescu, C.;
    • Trang‐Poisson, C.;
    • Altwegg, R.;
    • Marteau, P.;
    • Vaysse, T.;
    • Bourrier, A.;
    • Nancey, S.;
    • Laharie, D.;
    • Allez, M.;
    • Savoye, G.;
    • Moreau, J.;
    • Vuitton, L.;
    • Viennot, S.
    Publication type:
    Article
    14
    15
    16
    17
    18
    19
    20

    The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2017, v. 45, n. 4, p. 533, doi. 10.1111/apt.13897
    By:
    • Carrat, F.;
    • Seksik, P.;
    • Colombel, J.‐F.;
    • Peyrin‐Biroulet, L.;
    • Beaugerie, L.;
    • Colombel, Jean‐Frédéric;
    • Cosnes, Jacques;
    • Gendre, Jean‐Pierre;
    • Lémann, Marc;
    • Hébuterne, Xavier;
    • Cortot, Antoine;
    • Bouhnik, Yoram;
    • Laharie, David;
    • Dupas, Jean Louis;
    • Flourié, Bernard;
    • Lerebours, Eric;
    • Beaugerie, Laurent;
    • Peyrin‐Biroulet, Laurent;
    • Allez, Matthieu;
    • Messing, Bernard
    Publication type:
    Article
    21
    22
    23
    24
    25
    26
    27

    Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2016, v. 43, n. 2, p. 252, doi. 10.1111/apt.13466
    By:
    • Bourrier, A.;
    • Carrat, F.;
    • Colombel, J.‐F.;
    • Bouvier, A.‐M.;
    • Abitbol, V.;
    • Marteau, P.;
    • Cosnes, J.;
    • Simon, T.;
    • Peyrin‐Biroulet, L.;
    • Beaugerie, L.;
    • Gendre, Jean‐Pierre;
    • Lémann, Marc;
    • Hébuterne, Xavier;
    • Cortot, Antoine;
    • Bouhnik, Yoram;
    • Laharie, David;
    • Dupas, Jean Louis;
    • Flourié, Bernard;
    • Lerebours, Eric;
    • Allez, Matthieu
    Publication type:
    Article
    28

    Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2016, v. 43, n. 1, p. 61, doi. 10.1111/apt.13453
    By:
    • Coimbra, A. J. F.;
    • Rimola, J.;
    • O'Byrne, S.;
    • Lu, T. T.;
    • Bengtsson, T.;
    • Crespigny, A.;
    • Luca, D.;
    • Rutgeerts, P.;
    • Bruining, D. H.;
    • Fidler, J. L.;
    • Sandborn, W. J.;
    • Santillan, C. S.;
    • Higgins, P. D. R.;
    • Al‐Hawary, M. M.;
    • Vermeire, S.;
    • Vanbeckevoort, D.;
    • Vanslembrouck, R.;
    • Peyrin‐Biroulet, L.;
    • Laurent, V.;
    • Herrmann, K. A.
    Publication type:
    Article
    29
    30

    Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2015, v. 42, n. 8, p. 977, doi. 10.1111/apt.13363
    By:
    • Safroneeva, E.;
    • Vavricka, S. R.;
    • Fournier, N.;
    • Pittet, V.;
    • Peyrin‐Biroulet, L.;
    • Straumann, A.;
    • Rogler, G.;
    • Schoepfer, A. M.;
    • Bauerfeind, Peter;
    • Beglinger, Christoph;
    • Begré, Stefan;
    • Bengoa, José;
    • Binek, Janek;
    • Boller, Daniel;
    • Borovicka, Jan;
    • Braegger, Christian;
    • Burnand, Bernard;
    • Camara, Rafael;
    • Criblez, Dominique;
    • Saussure, Philippe
    Publication type:
    Article
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50